Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10419)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
ELOVL6
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) [Driver]
| In total 1 item(s) under this target | ||||
| Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
| Target for Ferroptosis | Driver | |||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Responsed Drug | Apatinib | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
In Vitro Model |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 |
| HIEC-6 cells | Normal | Homo sapiens | CVCL_6C21 | |
| Response regulation | ACSL4, a vital regulator of ferroptosis, could interact with ELOVL6 directly. Apatinib promoted ferroptosis in colorectal cancer (CRC) cells by targeting ELOVL6/ACSL4, providing a new mechanism support for apatinib application in the clinical treatment of CRC. | |||
Colorectal cancer [ICD-11: 2B91]
| In total 1 item(s) under this disease | ||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
| Target Regulator | Elongation of very long chain fatty acids protein 6 (ELOVL6) | Protein coding | ||
| Responsed Drug | Apatinib | Investigative | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
In Vitro Model |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 |
| HIEC-6 cells | Normal | Homo sapiens | CVCL_6C21 | |
| Response regulation | ACSL4, a vital regulator of ferroptosis, could interact with ELOVL6 directly. Apatinib promoted ferroptosis in colorectal cancer (CRC) cells by targeting ELOVL6/ACSL4, providing a new mechanism support for apatinib application in the clinical treatment of CRC. | |||
Apatinib
[Investigative]
| In total 1 item(s) under this drug | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
| Drug for Ferroptosis | Inducer | |||
| Response Target | Long-chain-fatty-acid--CoA ligase 4 (ACSL4) | Driver | ||
| Responsed Disease | Colorectal cancer | ICD-11: 2B91 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
In Vitro Model |
HCT 116 cells | Colon carcinoma | Homo sapiens | CVCL_0291 |
| HIEC-6 cells | Normal | Homo sapiens | CVCL_6C21 | |
| Response regulation | ACSL4, a vital regulator of ferroptosis, could interact with ELOVL6 directly. Apatinib promoted ferroptosis in colorectal cancer (CRC) cells by targeting ELOVL6/ACSL4, providing a new mechanism support for apatinib application in the clinical treatment of CRC. | |||
